Short-term stake in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) decreases 26.1%

0

Fresenius Medical Care AG & Co. KGaA (New York Stock Exchange: FMSGet a rating) was the target of a sharp drop in short-term interest rates during the month of April. As of April 15, there was short interest totaling 1,050,000 shares, down 26.1% from the March 31 total of 1,420,000 shares. Based on an average trading volume of 519,300 shares, the day-to-cover ratio is currently 2.0 days.

Shares of FMS inventory opened at $31.08 on Monday. The stock has a market capitalization of $18.21 billion, a P/E ratio of 15.78, a PEG ratio of 1.39 and a beta of 1.20. Fresenius Medical Care AG & Co. KGaA has a 52 week minimum of $28.75 and a 52 week maximum of $42.45. The company has a quick ratio of 0.82, a current ratio of 1.10 and a leverage ratio of 0.48. The company’s fifty-day simple moving average is $32.67 and its two-hundred-day simple moving average is $32.79.

Fresenius Medical Care AG & Co. KGaA (New York Stock Exchange: FMSGet a rating) last announced its quarterly results on Tuesday, February 22. The company reported EPS of $0.51 for the quarter, beating the consensus estimate of $0.50 by $0.01. The company posted revenue of $5.31 billion for the quarter, versus $5.38 billion expected by analysts. Fresenius Medical Care AG & Co. KGaA achieved a net margin of 5.51% and a return on equity of 7.51%. On average, analysts expect Fresenius Medical Care AG & Co. KGaA to post an EPS of 2.07 for the current financial year.

The company also recently declared an annual dividend, which will be paid on Friday, May 27. Shareholders of record on Monday, May 16 will receive a dividend of $0.7093. This represents a return of 3.4%. The ex-dividend date is Friday, May 13. The payout ratio of Fresenius Medical Care AG & Co. KGaA is currently 29.08%.

A number of hedge funds have recently changed their positions in FMS. First Trust Advisors LP increased its stake in Fresenius Medical Care AG & Co. KGaA by 12.5% ​​in Q1. First Trust Advisors LP now owns 86,559 shares of the company worth $3,508,000 after buying an additional 9,624 shares in the last quarter. Citadel Advisors LLC increased its stake in Fresenius Medical Care AG & Co. KGaA by 8.2% in the 2nd quarter. Citadel Advisors LLC now owns 20,662 shares of the company worth $859,000 after buying 1,558 additional shares in the last quarter. Millennium Management LLC acquired a new stake in Fresenius Medical Care AG & Co. KGaA in Q2 for a value of $266,000. Commonwealth Equity Services LLC increased its stake in Fresenius Medical Care AG & Co. KGaA by 11.7% in the third quarter. Commonwealth Equity Services LLC now owns 12,766 shares of the company worth $446,000 after purchasing an additional 1,334 shares last quarter. Finally, Raymond James & Associates increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 17.6% during the 3rd quarter. Raymond James & Associates now owns 55,821 shares of the company valued at $1,952,000 after purchasing an additional 8,339 shares last quarter. Institutional investors and hedge funds own 4.73% of the company’s shares.

Several brokerages have recently weighed in on FMS. StockNews.com began covering shares of Fresenius Medical Care AG & Co. KGaA in a Thursday, March 31 research note. They set a “buy” rating on the stock. Zacks Investment Research upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating and set a price target of $35.00 on the stock in a memo research on Tuesday, January 11. Societe Generale lowered its price target on shares of Fresenius Medical Care AG & Co. KGaA from €61.00 ($65.59) to €57.00 ($61.29) in a Friday 25 research note. february. Oddo Bhf has upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “outperforming” rating and has set a price target of €72.00 ($77.42) on the share in a Tuesday, March 1 research report. Finally, Credit Suisse Group lowered its price target on shares of Fresenius Medical Care AG & Co. KGaA from €66.00 ($70.97) to €61.00 ($65.59) in a note to research from Tuesday, March 1. Two investment analysts have assigned the stock a sell rating, eight have issued a hold rating and six have assigned the company a buy rating. According to MarketBeat.com, Fresenius Medical Care AG & Co. KGaA currently has a consensus rating of “Hold” and an average target price of $51.71.

Fresenius Medical Care AG & Co. KGaA Company Profile (Get a rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.

Further reading



Get news and reviews for Fresenius Medical Care AG & Co. KGaA Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com’s free daily email newsletter .

Share.

Comments are closed.